申请人:Masui Moriyasu
公开号:US20090062261A1
公开(公告)日:2009-03-05
It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.
A compound represented by:
wherein Z is N or CR
1
, A
1
is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A
2
is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R
1
, R
2
, R
a
, R
b
, R
c
and R
d
are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR
3
R
4
)m-, —CO(CR
3
R
4
)n-, —CONR
5
(CR
3
R
4
)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R
3
and R
4
are each independently hydrogen, halogen, hydroxy etc., and R
5
is hydrogen or lower alkyl,
or a pharmaceutically acceptable salt, or a solvate thereof.